SCHEMBL5566208

SCHEMBL5566208

O=C(O)c1ncn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O)n1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.78
▸ SMN1; SMN2 Q16637 3/20 0.78
▸ ALDH1A1 P00352 3/20 0.78
▸ TSHR P16473 2/20 0.78
▸ THPO P40225 2/20 0.78
▸ PMP22 Q01453 2/20 0.78
▸ GLA P06280 1/20 0.78
▸ EIF4E P06730 1/20 0.78
▸ CYP3A4 P08684 1/20 0.78
▸ TOP1 P11387 1/20 0.78
▸ ADORA1 P30542 1/20 0.78
▸ PNP P00491 3/20 0.70
▸ KDM4E B2RXH2 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ BLM P54132 2/20 0.48
▸ TP53 P04637 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ GMNN O75496 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15155278 1.00 LMNA (0.78) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL4195683 1.00 LMNA (0.78) LMNASMN1; SMN2ALDH1A1TSHRTHPO
Ribavirin SCHEMBL11368948 0.88 LMNA (0.95) LMNASMN1; SMN2ALDH1A1TSHRTHPO
Ribavirin SCHEMBL3727 0.88 LMNA (1.00) LMNASMN1; SMN2ALDH1A1TSHRTHPO
Ribavirin SCHEMBL5476700 0.88 LMNA (1.00) LMNASMN1; SMN2ALDH1A1TSHRTHPO
Ribavirin SCHEMBL4064991 0.88 LMNA (1.00) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL12901991 0.88 LMNA (0.76) LMNASMN1; SMN2ALDH1A1TSHRTHPO
Ribavirin SCHEMBL21311208 0.88 LMNA (1.00) LMNASMN1; SMN2ALDH1A1TSHRTHPO
Ribavirin SCHEMBL20806078 0.88 LMNA (1.00) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL13320541 0.88 LMNA (0.76) LMNASMN1; SMN2ALDH1A1TSHRTHPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285660-B2 for use as viricides; comprises the reaction of glycosylation of 3-substituted triazoles in the presence of a lewis acid and of a solvent ARCHIMICA S.R.L. (IT) 2007-10-23 — — US disclosed
EP-1414836-B1 PROCESS FOR THE PREPARATION OF L-RIBAVIRIN CLARIANT LSM ITALIA SPA (IT) 2004-12-29 — — EP disclosed
US-20040176587-A1 Process for the preparation of l-ribavirin ARCHIMICA S.R.L. (IT) 2004-09-09 — — US disclosed
EP-1414836-A2 PROCESS FOR THE PREPARATION OF L-RIBAVIRIN Clariant Life Science Molecules (Italia) SpA (IT) 2004-05-06 — — EP disclosed
WO-2003011883-A2 PROCESS FOR THE PREPARATION OF L-RIBAVIRIN CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) 2003-02-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176587-A1 Process for the preparation of l-ribavirin RNGTT, CPSF1, GART LMNA 906/4885SMN1; SMN2 3353/4885ALDH1A1 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback